Serum Institute of India (SII) was the world's largest manufacturer of vaccines and had signed an agreement to produce the Oxford vaccine, a top five candidate. The chief executive officer, Adar Poonawala, had announced in late July 2020 that the government of India had agreed to buy two doses of the vaccine, at a price of US$13 per dose. In early August, two developments caused Adar to revisit SII's initial pricing decision. The first development was that Russia had announced it had developed a vaccine that was ready for mass distribution in early October-two months ahead of SII. The second development was that Johnson & Johnson had announced a price of US$10 per dose. The case outlines the decisions facing SII concerning the pricing strategy and pricing dynamics for their COVID-19 vaccine. Malay Krishna is affiliated with SP Jain Institute of Management & Research. Sunny Arora is affiliated with SP Jain Institute of Management & Research.

【書誌情報】

ページ数：14ページ

サイズ：A4

商品番号：HBSP-W20983

発行日：2020/12/15

登録日：2021/2/19